ReviewInternational journal of molecular sciences2022
Hypertension and Type 2 Diabetes-The Novel Treatment Possibilities.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 72 citations in OpenAlex.
- Effects of Tai Chi and Qigong intervention on anxiety and stress in diabetic and hypertensive Brazilian patients: a randomized controlled trial.Einstein (Sao Paulo, Brazil) · 2025Trial
- Assessment of Selected Clinical Chemistry Analytes Among Hypertensive Patients at Wallaga University Referral Hospital, Nekemte, Oromia, Western Ethiopia: A Comparative Cross-Sectional Study.Health science reports · 2026Article
- Identification of bacterial key genes and therapeutic targets in hypertensive patients with type 2 diabetes through bioinformatics analysis.Scientific reports · 2026Article
- Diabetic Retinopathy Screening in Primary Care Real Practice: Study Procedures and Baseline Characteristics from the RETINAvalid Project.Healthcare (Basel, Switzerland) · 2026Article
- Article
- Ability of the DHAM Score to Predict 5-Year All-Cause Mortality in Patients With Diabetes and Comorbid Hypertension: Validation and Risk Stratification in Two Prospective Cohorts.Journal of diabetes research · 2026Article
- Knowledge, Attitudes, and Practices Regarding Venous Thromboembolism Among Elderly Chinese Patients: A Cross-Sectional Study.International journal of general medicine · 2026Article
- Prevalence and clinical correlates of diabetes in hospitalized heart failure patients: a retrospective study.Frontiers in endocrinology · 2026Article
- Sociodemographic Factors, Physical Activity and Glycemic Control in Adults with Diabetes: A Pilot Study from a Croatian Reference Center.Nursing reports (Pavia, Italy) · 2025Article
- Hypertension in type 2 diabetes mellitus: prevalence, patterns, determinants and implications for cardiovascular risk prediction in a population of Nigerian patients.Cardiovascular diabetology. Endocrinology reports · 2025Article
- Metagenomic profiling of gut microbime: associating their role with the advancement of diabetic nephropathy.Antonie van Leeuwenhoek · 2025Review
- Revisiting hypertension prevalence and risk factors: prevalence of hypertension and risk of diabetes in China.BMC cardiovascular disorders · 2025Article
- Predicting hypertension in type 2 diabetes mellitus: Insights from a nomogram model.World journal of diabetes · 2025Article
- Identify the co-expressed genes of hypertensive nephropathy and diabetic nephropathy.Scientific reports · 2025Article
- Scientometric analysis and historical review of diabetic encephalopathy research: Trends and hotspots (2004-2023).World journal of diabetes · 2025Article
- Life-threatening risk factors contribute to the development of diseases with the highest mortality through the induction of regulated necrotic cell death.Cell death & disease · 2025Review
- The use of statins are associated with an increased risk of new-onset diabetes in patients with hypertension and obstructive sleep apnoea, a longitudinal study.Diabetology & metabolic syndrome · 2025Article
- Article
- Hypertension and its determinants in Abu Dhabi population: a retrospective cohort study.Journal of hypertension · 2025Article
- The impact of glycated hemoglobin trajectories on hypertension risk: a retrospective cohort study.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Elevated blood pressure and hyperglycaemia frequently coexist and are both components of metabolic syndrome. Enhanced cardiovascular risk is strongly associated with diabetes and the occurrence of hypertension. Both hypertension and type 2 diabetes, if treated inappropriately, lead to serious complications, increasing the mortality of patients and generating much higher costs of health systems. This is why it is of great importance to find the missing link between hypertension and diabetes development and to simultaneously search for drugs influencing these two disorders or even drugs aimed at their pathological bases. Standard antihypertensive therapy mainly focuses on blood pressure reduction, while novel drugs also possess a wide range of pleiotropic modes of actions, such as cardio- and nephroprotective properties or body weight reduction. These properties are especially desirable in a situation when type 2 diabetes coexists with hypertension. This review describes the connections between diabetes and hypertension development and briefly summarises the current knowledge regarding attempts to define targets for the treatment of high blood pressure in diabetic patients. It also describes the standard hypotensive drugs preferred in patients with type 2 diabetes, as well as novel drugs, such as finerenone, esaxerenone, sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 analogues and sacubitril/valsartan.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.